摘要
目的探讨利奈唑胺注射液联合去甲万古霉素对肺部感染耐甲氧西林金黄色葡萄球菌(MRSA)患者内皮功能的影响。方法104例肺部感染MRSA患者随机分为两组,常规组给予去甲万古霉素治疗,联合组给予利奈唑胺注射液联合去甲万古霉素治疗,比较两组的MRSA清除率、内皮功能及不良反应。结果治疗后,联合组的MRSA清除率高于常规组,ET-1、vWF、NO水平均低于常规组(P<0.05)。两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论利奈唑胺注射液联合去甲万古霉素治疗肺部感染MRSA患者可有效清除MRSA,改善内皮功能,安全性较高。
Objective To explore the impact of linazolamide injection combined with norvancomycin on endothelial function of patients with pulmonary methicillin-resistant staphylococcus aureus(MRSA)infection.Methods 104 patients with pulmonary MRSA infection were randomly divided into two groups.The routine group was treated with norvancomycin,and the combined group was treated with linazolamide injection combined with norvancomycin.The MRSA clearance rate,endothelial function and adverse reactions were compared between the two groups.Results After treatment,the MRSA clearance rate ofthe combined group was higher than that of the routine group,and the levels of ET-1,vWF and NO were lower than those of the routine group(P<0.05).No significant difference was found in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Linazolamide injection combined with norvancomycin in the treatment of pulmonary MRSA infection can effectively remove MRSA and improve endothelial function,and has high safety.
作者
刘湾
杨彦伟
王艳娟
LIU Wan;YANG Yanwei;WANG Yanjuan(Pharmacy Department,the First Affiliated Hospital of He'nan University,Kaifeng 475000,China)
出处
《临床医学工程》
2023年第12期1663-1664,共2页
Clinical Medicine & Engineering
基金
河南省医学科技攻关计划(联合共建)项目(项目编号:LHGJ20220657)。
关键词
利奈唑胺
去甲万古霉素
肺部感染
耐甲氧西林金黄色葡萄球菌
内皮功能
Linazolamide
Norvancomycin
Pulmonary infection
Methicillin-resistant staphylococcus aureus
Endothelial function
